Exhibit 107
CALCULATION OF FILING FEE TABLE
Form S-8
Novo Nordisk A/S
Newly Registered Securities
| Security Type |
Security Title |
Fee Calculation Rule |
Amount Registered |
Proposed Per Unit |
Proposed Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration |
Carry Type |
Carry Forward File Number |
Carry Forward Initial Effective Date |
Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward | |||||||||||||
| Fees to be Paid |
Equity | B shares, nominal value DKK 0.20 per share | Rule 457(c) and Rule 457(h) | 5,000,000(1)(2) | $109.60 | $548,000,000.00 | $92.70 per $1,000,000.00 | $50,799.60 | — | — | — | — | ||||||||||||
| Fees Previously Paid |
— | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||
| Carry Forward Securities | ||||||||||||||||||||||||
| Carry Forward Securities |
— | — | — | — | — | — | — | — | — | |||||||||||||||
| Total Offering Amounts | $548,000,000.00 | $50,799.60 | ||||||||||||||||||||||
| Total Fees Previously Paid | — | |||||||||||||||||||||||
| Total Fee Offsets | — | |||||||||||||||||||||||
| Net Fee Due | $50,799.60 | |||||||||||||||||||||||
| (1) | The B shares may be represented by American Depository Shares (“ADSs”) of Novo Nordisk A/S (the “Registrant”), which are evidenced by American Depositary Receipts (“ADRs”). The ADSs have been registered under a separate registration statement filed by the Registrant with the U.S. Securities and Exchange Commission (the “Commission”) on Form F-6 on December 10, 2013 (File No. 333-192740), as amended by the Post-Effective Amendment No. 1 to Form F-6 filed by the Registrant with the Commission on March 2, 2017 (File No. 333-192740). Each ADS and ADR represents one B share. The Registrant’s ADRs are listed on the New York Stock Exchange (“NYSE”) under the symbol “NVO.” |
| (2) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 (this “Registration Statement”) also covers such additional shares as may hereinafter be offered or issued to prevent dilution resulting from stock splits, stock dividends, recapitalizations, or similar transactions. |
| (3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act, based upon the average of the high and low sales prices of the Registrant’s ADRs as reported by the NYSE on March 22, 2022, which date is within five business days prior to filing this Registration Statement. |